Evidence map›Paper›PMID 28880407›Full record

ArticleBritish journal of clinical pharmacology2017

Biomarkers in solid organ transplantation.

Teun van Gelder

Abstract readComment
In one paragraph

Article in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Biomarkers in solid organ transplantation.British journal of clinical pharmacology · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Teun van GelderDepartment of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recipients of solid organs such as the kidney and heart are treated with standard immunosuppressive regimens, and personalized medicine has not yet reached the clinic for this patient population. Biomarkers potentially will allow treatment regimens to be adjusted, according to the needs of the individual patient. Biomarkers may reflect the degree of immunosuppression of the immune system, or they may reflect early damage to the transplanted organ.

Indexed as

Kidney TransplantationMicroRNAsOrgan TransplantationBiomarkersChemokine CXCL10Graft RejectionHumansImmunosuppressive AgentsPrognosisBiomarkersChemokine CXCL10CXCL10 protein, humanImmunosuppressive AgentsMicroRNAsMIRN155 microRNA, humanbiomarkersimmunosuppressionrejectiontransplantation

Identifiers

PMID28880407
PMCPMC5698566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.